This landscape tracks 66,588 published patent records from 2015 through mid-2026 that combine antisense oligonucleotide or gapmer terminology with nuclease resistance, RNase H recruitment, chirality control or related chemistry terms. That figure is a records count, not a family-deduplicated count, and it reflects a specific search boundary around chemistry claims rather than every antisense-related filing in existence. Broader or narrower search terms would produce a different total, so treat this as the scope of this particular dataset rather than an absolute figure for the field.

The ranking in this dataset covers 100 assignees, with the leader holding 5,812 records and the top five combined accounting for 22.5% of all 66,588 records in scope. That leaves a long tail of smaller filers holding the remaining share individually. The concentration is meaningful but not extreme — the top ten together reach 29.7% of records, so most of the corpus sits outside the leading group.

Citation counts accumulate over time within a searched corpus, so older foundational patents on backbone modification and phosphorothioate chirality naturally out-cite newer filings even when the newer chemistry is more advanced. The most-cited record here, US5602240A, carries 4,271 citations largely because it established terminology and structural claims that later filings had to reference or design around. High citation counts should be read as a signal of influence on the field’s vocabulary and freedom-to-operate landscape, not as evidence that the underlying chemistry is still the state of the art.